OncLiveExpert Discusses Continued Growth of Immunotherapy in Gastric/GEJ CancerOncLive“Immunotherapy, in terms of biomarker-unselected populations, is probably the most promising [treatment] that we have identified in gastric/GEJ cancer,” said Harry … Continue reading
|
Next Steps in Research for Immunotherapy for HNSCC
OncLive So, I think that there’s going to be a lot of room for looking at combinations of existing therapies, whether they’re conventional DNA damage approaches or they’re targeted therapies with immunotherapy. I would encourage the people who are watching … |
|
Immunotherapy Toxicity Management in NSCLC
OncLive Everett Vokes, MD: Briefly, Roy, can you comment on toxicities with checkpoint inhibitors? What are toxicities community oncologists should know? Roy Herbst, MD, PhD: Right. And that’s the reason why we really want to make sure we have some efficacy. |